Financial Results: Page 5

Illumina reports 1% rise in third-quarter revenues
By LabPulse.com staff writers
Third-quarter revenue was $1.12 billion. For full-year 2022, the company expects consolidated revenue to be flat to 1% higher than fiscal year 2021.
November 7, 2022
Business Financial Results Social
Exact Sciences shares rise with 15% growth in Q3 revenues
By Leo O'Connor
Screening segment revenue, including sales for the Cologuard colon cancer molecular test, was $360.8 million, an increase of 29% year-over-year.
November 4, 2022
Colon Intestine Social
QuidelOrtho reports 54% rise in Q3 revenues, identifies additional cost synergies from business combination
By Leo O'Connor
The firm added that for the quarter ended October 2, its total supplemental combined revenue of $783.8 million decreased by 24%.
November 3, 2022
Financials Growth Revenue Business Social
Renalytix fiscal 2022 revenues double on sales for kidney health risk testing
By LabPulse.com staff writers
Among the highlights for the year, the company obtained reimbursement status for its KidneyIntelX test based on Medicare clinical lab fee schedule pricing of $950 per test.
October 31, 2022
Kidney
Hologic fiscal Q4 revenue drops 28% on COVID testing, supply chain challenges
By LabPulse.com staff writers
Excluding COVID-19, Diagnostics revenue grew 11% on an organic, constant currency basis.
October 31, 2022
Graph Financial Results Bar Chart Social
DiaSorin revenues rise 18% for 1st 9 months despite COVID sales decline
By LabPulse.com staff writers
Growth was driven in part by including Luminex, which contributed 277 million euros overall during the first nine months of 2022.
October 28, 2022
Graph Financial Results Tablet
Bio-Rad Laboratories Q3 revenues down 9% but beat analysts’ average estimate
By LabPulse.com staff writers
For the quarter ended September 30, COVID-related revenue was approximately $17 million compared to $57 million in the year-ago period.
October 28, 2022
Business Intelligence Social
Labcorp Q3 revenues drop 11% on decline in COVID-19 testing
By LabPulse.com staff writers
An almost 12% year-over-year decrease in COVID-19 PCR and antibody testing was partly offset by a 1.1% increase in Labcorp’s organic base business.
October 27, 2022
Business Financial Stock Drop Social
Thermo Fisher Scientific Q3 revenues rise 14% on strength in laboratory products, biopharma services
By LabPulse.com staff writers
In Q3, the firm’s Laboratory Products and Biopharma Services segment revenues were $5.59 billion, up 60% year-over-year compared to $3.49 billion.
October 26, 2022
Business Economics Pie Chart Social
BioMĂ©rieux Q3 sales rise 3% with higher-than-expected respiratory test demand
By LabPulse.com staff writers
In the third quarter, the France-based firm saw higher-than-expected demand for its BioFire molecular diagnostic respiratory panels for COVID-19 and other testing.
October 26, 2022
Coronavirus Business Graphic3 Social
Danaher Q3 diagnostics revenues rise 9%
By LabPulse.com staff writers
Third-quarter year-over-year core revenue growth within diagnostics was 14%, with Cepheid growing about 30%.
October 20, 2022
Financials Growth Revenue Business Social
Quest Diagnostics Q3 revenues drop 10% on COVID testing decline
By LabPulse.com staff writers
The Secaucus, NJ-based firm beat analysts’ average estimate for Q3 revenues of $2.35 billion and its shares rose in early Thursday trading on the NYSE.
October 20, 2022
Coronavirus Business Graphic2 Social
Previous Page
Page 5 of 12
Next Page